New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Eli Lilly announced new data showing that beta-amyloid imaging was associated with altered diagnosis and management of patients with Alzheimer's disease. Change in management was observed in both patients who met and did not meet the Appropriate Use Criteria, developed to provide guidance on which patients are most appropriate for imaging and how best to use the results. These data were presented by Andrew Siderowf, medical director, Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly. Results showed that 59% of subjects met the working definition of AUC. The proportion of patients with change in management plan was high for both AUC - 88% - and non-AUC - 77% - cases.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
10:45 EDTLLYOptions with increasing volume
Subscribe for More Information
10:43 EDTLLYEli Lilly calls active as shares at record high
Subscribe for More Information
10:09 EDTLLYHigh option volume stocks
Subscribe for More Information
08:03 EDTLLYEli Lilly and AstraZeneca enters into clinical trial collaboration
Subscribe for More Information
May 28, 2015
11:02 EDTLLYEli Lilly granted FDA orphan status for treatment of sickle cell disease
Subscribe for More Information
08:35 EDTLLYEli Lilly reports final results of Phase III trial for Alimta
Eli Lilly announced final results of the Phase III PROCLAIM trial, a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer, which evaluated Lilly's Alimta in combination with cisplatin with concurrent radiation followed by maintenance Alimta in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice. Those treated on the pemetrexed arm achieved a median overall survival of 26.8 months as compared to 25 months for those treated on the etoposide arm. Median progression-free survival was 11.4 months on the pemetrexed arm versus 9.8 months on the etoposide arm and an overall response rate of 35.9% on the pemetrexed arm and 33% on the etoposide arm.
08:09 EDTLLYEli Lilly to present data from several trials of Cyramza for cancer
Subscribe for More Information
May 27, 2015
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
May 22, 2015
10:52 EDTLLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use